Overview

Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
0
Participant gender:
Female
Summary
Uterine contraction has a negative impact on implantation and pregnancy rates. Inhibition of oxytocin receptors decreases uterine contraction frequency both on pregnant and non-pregnant women. Atosiban has been studied as an oxytocin antagonist to decrease uterine contraction frequency in order to increase implantation and pregnancy rates in assisted reproduction. Previous studies have studied 37,5mg total dose which was used both before and during embryo transfer, and found atosiban to be effective in increasing implantation and pregnancy rates. We aim to use a single dose of 6,75mg atosiban before embryo transfer, in order to decrease the dose and cost and possibly introduce a simpler protocol. Our study will also be the first randomized clinical study which investigates the effect of atosiban on frozen-thawed embryo transfer cycles.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bezmialem Vakif University
Collaborator:
Yeditepe University
Treatments:
Atosiban
Oxytocin
Vasotocin
Criteria
Inclusion Criteria:

- Infertile women applied to assisted reproduction clinic

- Follicle stimulating hormone < 12

- Body mass index < 25

- Patients whom antagonist protocol will be used

- Patients whom at least 2 good-quality embryos obtained

- Patients who are volunteer

Exclusion Criteria:

- Severe male factor (Sperm concentration <5 M/ml, progressive sperm motility <%10)

- Uterine anomaly

- Hydrosalphynx

- Difficult embryo transfer

- Patients who previously had a diagnosis of endometriosis and / or adenomyosis

- Endocrine problems (hypothyroidism, hyperthyroidism, hyperprolactinemia, premature
ovarian insufficiency)

- Having more than 3 in vitro fertilization failure

- Refusing to participate